OCEAN

Title

The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial (OCEAN)

Study outline

The OCEAN trial investigates whether successful long-term elimination of atrial fibrillation (AF) with percutaneous catheter ablation will result in a reduction in stroke risk sufficient to obviate the need for long-term oral anticoagulation (OAC).

Current Status

Patient enrolment ongoing in Canada and China
214 patients randomized
18 sites open for recruitment

Study set-up in preparation in Australia and Israel.
Site set-up ongoing in Germany, UK and Belgium. 
Status as of 5th January, 2018, updates are carried out quarterly.

Planned Number of Patients

1.572 (375 in Germany)

Participating Countries

Australia, Belgium, Canada, China, Germany, Israel, UK

Chief International Investigators

David H. Birnie, MD, Ottawa Heart Institute Research Corporation, Canada
Atul Verma, MD, Southlake Regional Health Center, Ontario, Canada
Gerhard Hindricks, MD, Leipzig Heart Centre, Germany

Overall Responsibility

Sponsor: Ottawa Heart Institute Research Corporation, Canada
Legal Sponsor Representative for Europe: Kompetenznetz Vorhofflimmern e.V.  (Atrial Fibrillation NETwork - AFNET), Münster, Germany 

Registration

NCT number: 02168829
EudraCT number: 2016-002353-38